TELA Bio (NASDAQ:TELA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02), Zacks reports. TELA Bio had a negative return on equity of 329.48% and a negative net margin of 54.12%.
TELA Bio Stock Down 2.6%
Shares of NASDAQ:TELA traded down $0.03 during midday trading on Thursday, reaching $1.11. 188,725 shares of the company were exchanged, compared to its average volume of 154,947. TELA Bio has a fifty-two week low of $0.86 and a fifty-two week high of $3.20. The company has a quick ratio of 2.59, a current ratio of 3.19 and a debt-to-equity ratio of 4.14. The stock has a fifty day simple moving average of $1.46 and a two-hundred day simple moving average of $1.58. The firm has a market cap of $43.98 million, a PE ratio of -0.99 and a beta of 0.89.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.50.
TELA Bio Company Profile
TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.
See Also
- Five stocks we like better than TELA Bio
- How to Use Stock Screeners to Find Stocks
- Disney’s 2026 Outlook Brightens Under Iger’s Magic Touch
- Best Energy Stocks – Energy Stocks to Buy Now
- Forget Netflix—Paramount Skydance’s $3B Plan Is Turning Heads on Wall Street
- How to Choose Top Rated Stocks
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
